• 1
    Cannistra SA. Cancer of the ovary. New Engl J Med 1993; 329: 15501559.
  • 2
    Lee HP, Seo SS, Ryu SY et al. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecol Oncol 2008; 109: 359363.
  • 3
    Kim HS, Kang SB, Seo SS et al. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer. Ann N Y Acad Sci 2009; 1171: 627634.
  • 4
    Nam EJ, Kim JW, Kim JH et al. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer. Am J Clin Oncol 2010; 33: 233237.
  • 5
    Choi CH, Lee YY, Song TJ et al. Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. Cancer 2011; 117: 21042111.
  • 6
    Hwang JH, Yoo HJ, Lim MC, Seo SS, Park SY, Kang S. Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer. Anticancer Drugs 2012; 23: 321325.
  • 7
    Kim HS, Park NH, Kang S et al. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. J Obstet Gynaecol Res 2010; 36: 8693.
  • 8
    Kim YM, Lee SW, Kim DY, Kim JH, Nam JH, Kim YT. The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. J Chemother 2010; 22: 197200.
  • 9
    Zamboni WC, Ramalingam S, Friedland DM et al. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res 2009; 15: 14661472.